Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma-Reference-Cited by-全球学者库

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

Published:2019-08-27 Issue:8 Volume:322 Page:746
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Park Julie R.¹²,Kreissman Susan G.³,London Wendy B.⁴,Naranjo Arlene⁵,Cohn Susan Lerner⁶,Hogarty Michael D.⁷,Tenney Sheena C.⁵,Haas-Kogan Daphne⁸,Shaw Peter John⁹,Kraveka Jacqueline M.¹⁰,Roberts Stephen S.¹¹,Geiger James Duncan¹²,Doski John J.¹³,Voss Stephan D.¹⁴,Maris John M.⁷,Grupp Stephan A.⁷,Diller Lisa⁴

Affiliation:

1. Department of Pediatrics, Seattle Children’s Hospital, Seattle, Washington

2. University of Washington, Seattle

3. Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina

4. Department of Pediatrics, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts

5. Department of Biostatistics, University of Florida, Children’s Oncology Group Statistics and Data Center, Gainesville

6. Department of Pediatrics, University of Chicago, Chicago, Illinois

7. Department of Pediatrics Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

8. Department of Radiation Oncology, Dana Farber/Brigham and Women’s Cancer Center and Harvard Medical School, Boston, Massachusetts

9. Bone Marrow Transplant, Children's Hospital at Westmead, Sydney, Australia

10. Department of Pediatrics, Medical University of South Carolina, Charleston

11. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Manhattan, New York

12. Section of Pediatric Surgery, CS Mott Children’s Hospital, Michigan Medicine, Ann Arbor

13. Departments of Surgery and Pediatrics, UT Health San Antonio, San Antonio, Texas

14. Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/article-pdf/322/8/746/17861216/jama_park_2019_oi_190086.pdf

Reference41 articles.

1. Neuroblastoma.;Matthay;Nat Rev Dis Primers,2016

2. Advances in risk classification and treatment strategies for neuroblastoma.;Pinto;J Clin Oncol,2015

3. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.;Berthold;Br J Cancer,2018

4. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.;Kreissman;Lancet Oncol,2013

5. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.;Ladenstein;Lancet Oncol,2017

Cited by 212 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year Experience;Practical Radiation Oncology;2024-02

2. Evolution and contemporary role of metronomic chemotherapy in the treatment of neuroblastoma;Cancer Letters;2024-02

3. Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects;Cancers;2024-01-26

4. IV Joint Congress of RSPOH “Actual problems and prospects for the development of pediatric oncology and hematology in the Russian Federation – 2023”. Resolution on the results of the satellite symposium “Tepadina in oncohematology: forgotten opportunities and new horizons”;Russian Journal of Pediatric Hematology and Oncology;2024-01-16

5. Transmembrane serine protease 6, a novel target for inhibition of neuronal tumor growth;Cell Death & Disease;2024-01-13